共 50 条
- [1] Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III StudyBIODRUGS, 2021, 35 (06) : 735 - 748Feldman, Steven R.Reznichenko, NataliyaPulka, GrazynaKingo, KulliGaldava, GeorgeBerti, FaustoSobierska, JoannaDias, RoshanGuenzi, EricOtto, HendrikHaliduola, Halimu N.Kay, RichardStroissnig, Heimo
- [2] Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group StudyBioDrugs, 2023, 37 : 551 - 567Steven R. FeldmanRichard KayNataliya ReznichenkoJoanna SobierskaRoshan DiasHendrik OttoHalimu N. HaliduolaAbid SattarRuth RuffieuxHeimo StroissnigFausto Berti
- [3] Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate-to-Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group StudyBIODRUGS, 2023, 37 (04) : 551 - 567Feldman, Steven R. R.Kay, RichardReznichenko, NataliyaSobierska, JoannaDias, RoshanOtto, HendrikHaliduola, Halimu N. N.Sattar, AbidRuffieux, RuthStroissnig, HeimoBerti, Fausto
- [4] A RANDOMISED, DOUBLE-BLIND TRIAL COMPARING THE EFFICACY, SAFETY AND IMMUNOGENICITY OF MSB11022, A PROPOSED BIOSIMILAR OF ADALIMUMAB, VERSUS ADALIMUMAB ORIGINATOR IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASISANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1602 - 1602Hercogova, J.Papp, K. A.Edwards, C. J.Chyrok, V.Halady, T.Ullmann, M.Vlachos, P.
- [5] A randomized double-blind trial comparing the efficacy, safety, and immunogenicity of MSB11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB21 - AB21Hercogova, JanaPapp, Kim A.Edwards, Christopher J.Chyrok, VeranikaHalady, TanujaUllman, MartinVlachos, Pantelis
- [6] A randomized, double-blind, multicenter study to compare the efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (GP2017) with originator adalimumab in patients with moderate-to-severe chronic plaque-type psoriasisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB22 - AB22Blauvelt, AndrewFowler, Joseph, Jr.Schuck, EllenJauch, JuliaWoehling, HeikeLeonardi, Craig
- [7] Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III StudyAdvances in Therapy, 2022, 39 : 583 - 597Lin CaiLinfeng LiHao ChengYangfeng DingZhenshu BiaoShifa ZhangSongmei GengQuanzhong LiuHong FangZhiqi SongYan LuShanshan LiQing GuoJuan TaoLi HeJun GuQinping YangXiuping HanXinghua GaoDanqi DengShenqiu LiQingyu WangJun ZhuJianzhong Zhang
- [8] Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III StudyADVANCES IN THERAPY, 2022, 39 (01) : 583 - 597Cai, LinLi, LinfengCheng, HaoDing, YangfengBiao, ZhenshuZhang, ShifaGeng, SongmeiLiu, QuanzhongFang, HongSong, ZhiqiLu, YanLi, ShanshanGuo, QingTao, JuanHe, LiGu, JunYang, QinpingHan, XiupingGao, XinghuaDeng, DanqiLi, ShenqiuWang, QingyuZhu, JunZhang, Jianzhong
- [9] Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyBIODRUGS, 2024, 38 (01) : 121 - 131Papp, Kim A.Lebwohl, Mark G.Thaci, DiamantJaworski, JanuszKwiek, BartlomiejTrefler, JakubDudek, AnnaSzepietowski, Jacek C.Reznichenko, NataliyaNarbutt, JoannaBaran, WojciechKolinek, JoannaDaniluk, StefanBartnicka-Maslowska, KatarzynaReich, AdamAndrashko, YuriyKim, SunghyunBae, YunjuJeon, DabeeJung, JinsunLee, HyunseungPyo, TinaKo, Woori
- [10] Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyBioDrugs, 2024, 38 : 121 - 131Kim A. PappMark G. LebwohlDiamant ThaçiJanusz JaworskiBartlomiej KwiekJakub TreflerAnna DudekJacek C. SzepietowskiNataliya ReznichenkoJoanna NarbuttWojciech BaranJoanna KolinekStefan DanilukKatarzyna Bartnicka-MaslowskaAdam ReichYuriy AndrashkoSunghyun KimYunju BaeDabee JeonJinsun JungHyunseung LeeTina PyoWoori Ko